| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet; Departments of 2 Oncology and 3 Public Health Sciences, Karolinska University Hospital, Solna, Stockholm, Sweden
Requests for reprints: Lena Rosenberg, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, P.O. Box 281, SE-171 77 Stockholm, Sweden. Phone: 46-8-5248-6163 or 46-73-646-12-10; Fax: 46-8-31-49-75. E-mail: lena.u.rosenberg{at}ki.se
The effect of classic breast cancer risk factors on hormone receptor-defined breast cancer is not fully clarified. We explored these associations in a Swedish population-based study. Postmenopausal women ages 50 to 74 years, diagnosed with invasive breast cancer during 1993 to 1995, were compared with 3,065 age frequency-matched controls. We identified 332 estrogen receptor (ER–) and progesterone receptor (PR–) negative, 286 ER+PR–, 71 ER–PR+, 1,165 ER+PR+, and 789 tumors with unknown receptor status. Unconditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (95% CI). Women ages 
30 years, compared with those ages 20 to 24 years at first birth, were at an increased risk of ER+PR+ tumors (OR, 1.5; 95% CI, 1.2-1.8) but not ER–PR– tumors (OR, 1.1; 95% CI, 0.8-1.6). Women who gained 30 kg in weight during adulthood had an 
3-fold increased relative risk of ER+PR+ tumors (OR, 2.7; 95% CI, 1.9-3.8), but no risk increase of ER–PR– tumors (OR, 1.0; 95% CI, 0.5-2.1), compared with women who gained <10 kg. Compared with never users, women who used menopausal estrogen-progestin therapy for at least 5 years were at increased risk of ER+PR+ tumors (OR, 3.0; 95% CI, 2.1-4.1) but not ER–PR– tumors (OR, 1.3; 95% CI, 0.7-2.5). In conclusion, other risk factors were similarly related to breast cancer regardless of receptor status, but high age at first birth, substantial weight gain in adult age, and use of menopausal estrogen-progestin therapy were more strongly related to receptor-positive breast cancer than receptor-negative breast cancer. (Cancer Epidemiol Biomarkers Prev 2006;15(12):2482–8)
This article has been cited by other articles:
|
|
 |
|
  S. Deandrea, R. Talamini, R. Foschi, M. Montella, L. Dal Maso, F. Falcini, C. La Vecchia, S. Franceschi, and E. Negri Alcohol and Breast Cancer Risk Defined by Estrogen and Progesterone Receptor Status: A Case-Control Study Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2025 - 2028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Phipps, K. E. Malone, P. L. Porter, J. R. Daling, and C. I. Li Body Size and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2078 - 2086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hedelin, M. Lof, M. Olsson, H. Adlercreutz, S. Sandin, and E. Weiderpass Dietary Phytoestrogens Are Not Associated with Risk of Overall Breast Cancer But Diets Rich in Coumestrol Are Inversely Associated with Risk of Estrogen Receptor and Progesterone Receptor Negative Breast Tumors in Swedish Women J. Nutr., May 1, 2008; 138(5): 938 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Figueiredo, L. Bernstein, M. Capanu, K. E. Malone, C. F. Lynch, H. Anton-Culver, M. Stovall, L. Bertelsen, R. W. Haile, and J. L. Bernstein Oral Contraceptives, Postmenopausal Hormones, and Risk of Asynchronous Bilateral Breast Cancer: The WECARE Study Group J. Clin. Oncol., March 20, 2008; 26(9): 1411 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fournier, A. Fabre, S. Mesrine, M.-C. Boutron-Ruault, F. Berrino, and F. Clavel-Chapelon Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor-Defined Invasive Breast Cancer J. Clin. Oncol., March 10, 2008; 26(8): 1260 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Chlebowski, G. L. Anderson, D. S. Lane, A. K. Aragaki, T. Rohan, S. Yasmeen, G. Sarto, C. A. Rosenberg, F. A. Hubbell, and For the Women's Health Initiative Investigators Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status J Natl Cancer Inst, November 21, 2007; 99(22): 1695 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Veronesi, P. Maisonneuve, and A. Decensi Tamoxifen: An Enduring Star J Natl Cancer Inst, February 21, 2007; 99(4): 258 - 260. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
